{"analyses":[{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".0054","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1"},{"groupId":"OG001","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"In randomized subjects with baseline platelet ≤ 100 x 10\\^9/L, the proportion of subjects who achieved platelet \\>100 x 10\\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.","groups":[{"description":"Ibrutinib 420 mg daily.","id":"OG000","title":"Ibrutinib"},{"description":"Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles","id":"OG001","title":"Chlorambucil"}],"paramType":"NUMBER","populationDescription":"Subjects With Baseline Thrombocytopenia","reportingStatus":"POSTED","timeFrame":"Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.","title":"Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}